Stryker Corp under investigation for possible securities fraud

Stryker Corporation is under investigation by Law Offices of Howard G. Smith for potential securities law violations. Shares fell 6.43% to $325.70 on July 31, 2026, following Q2FY26 results citing supply disruptions. A further 8.8% drop to $276.43 occurred on September 8, 2026, after CFO confirmed issues continuing into Q3. Investors who suffered losses are advised to contact the law firm to discuss potential claims.

Cooper Companies faces securities fraud probe after guidance cuts

Shares fell 14.67% to $54.17 after Q3 results and guidance cuts. Full-year revenue guidance reduced by 1.4% to $4.24 billion. EPS guidance lowered by 1.8% to a range of $4.51 to $4.55. Company attributed guidance cut entirely to U.S. channel inventory reductions.

Stryker appoints Spencer Stiles as CEO effective January 2027

Spencer Stiles appointed CEO effective January 1, 2027. Kevin Lobo transitions to Executive Chair of the Board. Stiles currently serves as President and COO. Appointment includes membership on the Board of Directors.

Stryker faces probe over Peripheral Vascular manufacturing disclosures

Stryker shares fell $26.70 (-8.8%) on September 8, 2026, wiping over $10 billion in market capitalisation after the CFO disclosed a persisting manufacturing issue. Hagens Berman has opened an investigation into whether Stryker violated federal securities laws through inadequate disclosures about its Peripheral Vascular unit. On July 30, 2026, management had assured investors the backorder situation would reach a manageable level by end of Q3; the CFO later contradicted this at the Wells Fargo Healthcare Conference. Stryker acquired Inari Medical in February 2025 to supplement its Peripheral Vascular reporting unit, which is at the centre of the disclosure concerns. Shares had already fallen $22.34 (-6.4%) the day after the July 30, 2026 earnings call when supply disruptions were first disclosed.

Pomerantz probes Stryker over vascular supply delays

Pomerantz LLP investigates Stryker for securities fraud regarding vascular supply delays. Shares fell $26.70 (8.81%) on Sept 8 after CFO confirmed disruptions extend to Q4FY26. Hagens Berman also probes transparency regarding Inari Medical operations.

Block & Leviton probes Stryker over securities fraud claims

Block & Leviton investigates Stryker for potential securities law violations. Stryker CEO claimed in July that a manufacturing issue was addressed. CFO revealed in September that the problem persists into Q4. Stryker shares fell roughly 8% following the September disclosure. Investors who lost money on SYK stock may be eligible for recovery.